ArticleBMJ open2023

Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.

Jinping Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.